Full text is available at the source.
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Combined GIP and GLP-1 receptor therapies for diabetes and weight loss: chemistry, body effects, and medical uses
AI simplified
Abstract
Tirzepatide is the first monomeric peptide with dual activity at both incretin receptors.
- The incretin system is crucial for regulating metabolism after eating.
- Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are key hormones in this system.
- Pharmacological activation of GLP-1R is effective for managing high blood sugar and aiding weight loss.
- Clinical trials have demonstrated that tirzepatide significantly lowers blood glucose and body weight.
- The development of monomeric multi-incretin receptor agonists like tirzepatide represents an advancement in treating metabolic disorders.
AI simplified